<DOC>
	<DOCNO>NCT00502099</DOCNO>
	<brief_summary>Genotype 4 hepatitis C virus cause approximately 20 % 170 million case chronic hepatitis C world . Although rare western nation , genotype 4 common variant hepatitis C virus Egypt also find throughout Africa Middle East . Early report treatment patient genotype 4 chronic hepatitis C interferon-alfa ( IFN ) -alfa monotherapy indicate poor rate sustain viral response ( SVR ) . With introduction ribavirin combination therapy pegylation IFN alfa molecule , however , response rate improve dramatically , current clinical trial data indicate SVR rate 43 79 % attainable genotype 4 patient receive pegylated IFN alfa plus ribavirin 48 week . Clinical advance optimize treatment patient also make , tailor treatment option develop comparable treatment approach genotype 1 , 2 , 3 patient . A treatment duration 36 48 week appear optimal patient chronic hepatitis C genotype 4.The aim study assess efficacy safety pegylated interferon alpha 2a patient chronic hepatitis C genotype 4 comparison historical cohort patient treat pegylated interferon alpha 2b</brief_summary>
	<brief_title>Comparison Pegasys Versus Peg-Intron Treatment Chronic Hepatitis C Genotype 4</brief_title>
	<detailed_description>The treatment chronic hepatitis C interferon ( IFN ) -based medicine advance steadily since publication first clinical trial late 1980s.Initial intervention use IFN-alfa monotherapy achieve limited success , introduction IFN-alfa plus ribavirin combination therapy pegylation IFN alfa molecule , improve pharmacokinetics simplify dose regimen , result steady improvement overall treatment outcome . Sustained virologic response ( SVR , define undetectable HCV RNA 24 week complete treatment ) increase 6 % IFN alfa monotherapy 50 % pegylated interferon alfa ( PEG-IFN alfa ) plus ribavirin regimensObservations specific genotype 4 chronic hepatitis C follow similar path , initial investigation IFN-alfa monotherapy produce limited success .These study find IFN-alfa monotherapy , usually administer dose 3-5 MIU three time week six month , result SVR 5-25 % treated patient . [ 24-26 ] The subsequent inclusion ribavirin treatment regimens dramatic improvement SVR attainment , rate 8 42 % report patient receive IFN-alfa alone combination ribavirin ( 1000-1200 mg/day ) , respectively . Pegylation IFN alfa molecule next major advance treatment genotype 4 chronic hepatitis C.Although two early study fail demonstrate significant difference SVR rate PEG-IFN alfa-2b plus ribavirin native IFN alfa-2b plus ribavirin ( e.g. , 42.9 % vs. 32.3 % , p = 0.43 ) [ 27 ] , subsequent investigation report SVR rate 50 79 % patient receive PEG-IFN alfa-2b plus ribavirin ( 800-1,200 mg/day ) 48 week . [ Overall , meta-analysis clinical trial data show SVR rate significantly high among genotype 4 patient receive PEG-IFN alfa plus ribavirin receive IFN-alfa plus ribavirin ( 55 % vs. 30 % , p = 0.0088 ) . [ 33 ] This analysis also confirm importance adequate ribavirin dose high SVR rate patient receive PEG-IFN alfa combination high-dose ( 1000Â¬-1200 mg/day ) low-dose ( 800 mg/day ) ribavirin ( 72.0 45.8 % , respectively ; p value present ) . The importance ribavirin dose genotype 4 patient chronic hepatitis C also demonstrate analysis genotype 4 patient include registration study PEG-IFN alfa-2a . [ 22 , 34 ] In analysis , SVR rate 79 % among patient receive PEG-IFN alfa-2a ( 180 mcg/week ) plus ribavirin ( 1000-1200 mg/day ) 48 week compare 63 % receive regimen plus low dose ribavirin ( 800 mg/day ) .The optimization treatment duration critical ensuring SVR rate maximize without expose patient unnecessarily long treatment regimen may unfavorable implication term cost tolerability . The question optimal treatment duration genotype 4 chronic hepatitis C address prospective randomize study patient receive PEG-IFN alfa-2b ( 1.5 mcg/kg/week ) plus ribavirin ( 1000-1200 mg/day ) 24 , 36 , 48 weeks.Overall , SVR rate significantly high patient receive treatment 36 48 week treat 24 week ( 66 69 % vs. 29 % ; p = 0.001 comparison ) ( Fig . 2 ) . Relapse appear major factor determine treatment outcome : virologic relapse follow-up high among patient treat 24 week ( 20 45 , 44 % ) relatively rare among longer treatment arm . There significant difference 36-week 48-week treatment regimens overall cohort . However , among patient baseline viral load &gt; 2 million copies/mL attain SVR , 65 % treat 48 week 35 % treat 36 week : patient high baseline viral load treat 24 week fail attain SVR . This suggest 48-week treatment regimen may well suit patient high baseline viremia . The efficacy safety pegylated interferon 2a adequately evaluate chronic hepatitis C genotype 4 patient well conduct clinical trial involve well characterize cohort long follow .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>1 . Adult men woman 2 . Age : 25 55 year document chronic hepatitis 3 . Elevated serum alanine aminotransferase least 2 time upper limit normal ( 40 U/L ) 2 occasion precede 6 month 4 . Detectable antiHCV antibody status assess secondgeneration enzymelinked immunosorbent assay ( Roche Diagnostics , Branchburg , New Jersey ) ; 5 . Detectable HCV RNA polymerase chain reaction ( Cobas Amplicor HCV Monitor v2.0 [ Roche Diagnostics , Branchburg , New Jersey ] ; low limit quantitation [ 50 IU/mL ] ) 5 . Infection HCV genotype 4 6 . Histologic evidence chronic hepatitis C liver biopsy specimen obtain within precede year . 1 . Hepatitis A , hepatitis B , autoimmune hepatitis , alcoholic liver disease , druginduced hepatitis . 2 . Decompensated liver disease history variceal hemorrhage , ascites , hepatic encephalopathy . 3 . Patients coinfected schistosomiasis human immunodeficiency virus 4. leukocyte count lower 3000 /mm3 , neutropenia ( &lt; 1500 cells/mm3 ) , hemoglobin level lower 12 g/dL woman low 13 g/dL men , thrombocytopenia ( &lt; 90,000 cells/mm3 ) , creatinine concentration 1.5 time upper limit normal 5 . Organ transplantation 6 . Neoplastic disease 7 . Severe cardiac pulmonary disease 8 . Unstable thyroid dysfunction 9 . Psychiatric disorder 10 . Current pregnancy breast feeding . 11 . Therapy immunomodulatory agent within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>pegylated interferon alfa-2a</keyword>
	<keyword>ribavirin , rapid virologic response</keyword>
	<keyword>early virologic response</keyword>
	<keyword>sustain virologic response</keyword>
</DOC>